<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35452519</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.</ArticleTitle><Pagination><StartPage>1232</StartPage><EndPage>1234</EndPage><MedlinePgn>1232-1234</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ciac226</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciac226</ELocationID><Abstract><AbstractText>In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaylis</LastName><ForeName>Norman B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Arthritis &amp; Rheumatic Disease Specialties, Aventura, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritter</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Advanced Research &amp; Education, Gainesville, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>CytoDyn, Vancouver, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourhassan</LastName><ForeName>Nader Z</ForeName><Initials>NZ</Initials><AffiliationInfo><Affiliation>CytoDyn, Vancouver, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiwary</LastName><ForeName>Meenakshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health &amp; Science University, Beaverton, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacha</LastName><ForeName>Jonah B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health &amp; Science University, Beaverton, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Scott G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health &amp; Science University, Beaverton, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recknor</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CytoDyn, Vancouver, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Otto O</ForeName><Initials>OO</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04678830</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019742">Chemokines, CC</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2022 Oct 12;75(8):1485-1486. doi: 10.1093/cid/ciac389</RefSource><PMID Version="1">35819236</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019742" MajorTopicYN="N">Chemokines, CC</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019713" MajorTopicYN="N">Receptors, CCR5</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CCR5</Keyword><Keyword MajorTopicYN="N">immunosuppression</Keyword><Keyword MajorTopicYN="N">leronlimab</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. S. A. K., N. Z. P., and C. R. are officers of CytoDyn Inc and report stock options and consulting fees from CytoDyn, assistance with manuscript preparation (Medical Expressions, paid by CytoDyn), and other financial or nonfinancial interests as employees of CytoDyn. J. B. S., S. G. H., and O. O. Y. are paid consultants for CytoDyn Inc. J. B. S. reports stock options available for purchase from CytoDyn and assistance with manuscript preparation (Medical Expressions, paid by CytoDyn). S. G. H. reports stock options and receipt of leronlimab for CCR5 receptor occupancy assay from CytoDyn and assistance with manuscript preparation (Medical Expression, paid by CytoDyn). O. O. Y. reports assistance in writing the manuscript (paid by CytoDyn). M. T. reports assistance with manuscript preparation (Medical Expressions, paid by CytoDyn). N. B. G. was a principal investigator for this trial, serves on the CytoDyn Inc Scientific Advisory Board with stock options, and reports assistance with manuscript preparation (Medical Expressions, paid by CytoDyn). A. R. was a principal investigator for this trial and worked as an employee at the Center for Advanced Research &amp; Education, Gainesville, Georgia, which is performing a clinical research trial for CytoDyn. A. R. reports assistance with manuscript preparation (Medical Expressions, paid by CytoDyn). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35452519</ArticleId><ArticleId IdType="pmc">PMC9383814</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac226</ArticleId><ArticleId IdType="pii">6572226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis &#xa0;HE, Assaf &#xa0;GS, McCorkell &#xa0;L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. &#xa0;EClinicalMedicine &#xa0;2021; 38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangelista &#xa0;L, Vento &#xa0;S. &#xa0;The expanding therapeutic perspective of CCR5 blockade. &#xa0;Front Immunol &#xa0;2017; 8:1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5770570</ArticleId><ArticleId IdType="pubmed">29375583</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranova &#xa0;A, Cao &#xa0;H, Zhang &#xa0;F. &#xa0;Unraveling risk genes of COVID-19 by multi-omics integrative analyses. &#xa0;Front Med (Lausanne) &#xa0;2021; 8:738687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8452849</ArticleId><ArticleId IdType="pubmed">34557504</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantalupo &#xa0;S, Lasorsa &#xa0;VA, Russo &#xa0;R, et al. . Regulatory noncoding and predicted pathogenic coding variants of CCR5 predispose to severe COVID-19. &#xa0;Int J Mol Sci &#xa0;2021; 22:5372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8161088</ArticleId><ArticleId IdType="pubmed">34065289</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuesta-Llavona &#xa0;E, G&#xf3;mez &#xa0;J, Albaiceta &#xa0;GM, et al. . Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity. &#xa0;Int Immunopharmacol &#xa0;2021; 98:107825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8169316</ArticleId><ArticleId IdType="pubmed">34116286</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhody &#xa0;K, Pourhassan &#xa0;N, Kazempour &#xa0;K, et al. . PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. &#xa0;HIV Clin Trials &#xa0;2018; 19:85&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">29676212</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson &#xa0;JM, Lalezari &#xa0;JP, Thompson &#xa0;MA, et al. . Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. &#xa0;Antimicrob Agents Chemother &#xa0;2010; 54:4137&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944554</ArticleId><ArticleId IdType="pubmed">20660677</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson &#xa0;JM, Saag &#xa0;MS, Thompson &#xa0;MA, et al. . Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. &#xa0;J Infect Dis &#xa0;2008; 198:1345&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">18771406</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson &#xa0;JM, Thompson &#xa0;MA, Lalezari &#xa0;JP, et al. . Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. &#xa0;J Infect Dis &#xa0;2010; 201:1481&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856743</ArticleId><ArticleId IdType="pubmed">20377413</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson &#xa0;BK, Seethamraju &#xa0;H, Dhody &#xa0;K, et al. . CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. &#xa0;Int J Infect Dis &#xa0;2021; 103:25&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654230</ArticleId><ArticleId IdType="pubmed">33186704</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson &#xa0;WC, Rabut &#xa0;GE, Nagashima &#xa0;KA, et al. . Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. &#xa0;J Virol &#xa0;1999; 73:4145&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104194</ArticleId><ArticleId IdType="pubmed">10196311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang &#xa0;XL, Webb &#xa0;GM, Wu &#xa0;HL, et al. . Antibody-based CCR5 blockade protects macaques from mucosal SHIV transmission. &#xa0;Nat Commun &#xa0;2021; 12:3343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184841</ArticleId><ArticleId IdType="pubmed">34099693</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang &#xa0;XL, Wu &#xa0;HL, Webb &#xa0;GM, et al. . CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody leronlimab. Front Immunol &#xa0;2021; 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8640501</ArticleId><ArticleId IdType="pubmed">34868084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellado &#xa0;M, Rodr&#xed;guez-Frade &#xa0;JM, Vila-Coro &#xa0;AJ, et al. . Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J &#xa0;2001; 20:2497&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125458</ArticleId><ArticleId IdType="pubmed">11350939</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>